I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and now Xconomy.
Epizyme (NASDAQ: EPZM) said Monday that a pediatric patient taking its experimental cancer drug tazemetostat developed a new cancer, different than the one tazemetostat had been treating. The secondary cancer,... Read more »
The biggest news this week was in oncology, hands down. Merck showed that its immunotherapy pembrolizumab (Keytruda) might become a common option for many patients newly diagnosed with advanced lung cancer,... Read more »
[Editor’s note: Ben Fidler co-authored this report.] A decade from now, it’s possible that immunotherapy will have made a big dent in lung cancer, which is by far the... Read more »
Happy Friday, everyone. We’ll start this week with biotech deals, one featuring a couple of CAR-T heavyweights who have re-emerged after selling Kite Pharma for $12 billion. They will try to... Read more »
In the race to treat the fatty liver disease known as NASH, brought on by the modern obesity epidemic, much of the attention has focused on the U.S. But a new... Read more »
TCR² Therapeutics has raised a $125 million Series B round to push ahead with live, cancer-fighting T cells.
T cell receptor (TCR) therapies, the firm’s area of focus, have not progressed... Read more »
Charged with what the U.S. Securities and Exchange Commission called “massive fraud,” Theranos CEO Elizabeth Holmes has cut a deal with the agency.
The SEC charged Holmes and the... Read more »
Trump administration health officials were out on the stump this week, talking tough about drug prices and healthcare value, encouraging the private sector to take the lead but letting everyone know... Read more »
The cholesterol brawl is heating up again.
A pair of next-generation cholesterol-lowering drugs known as PCSK9 inhibitors came to market in 2015 and have since struggled to gain traction. Now Ann... Read more »
Thanks to advertising blitzes from companies like Ancestry.com and 23andMe, Joe and Jane Consumer might know that their genetic blueprint and $100 or so can dig up insights about their genealogy.... Read more »
Another week of White House chaos and American gun violence. Amid it all, we tried to parse what the Trump administration’s 2019 budget proposal meant for the biomedical and life-science worlds.... Read more »
When it comes to spending cash on potential combinations for its cancer immunotherapy drugs, Bristol-Myers Squibb (NYSE: BMY) isn’t afraid of the b-word: billions.
The New York-based pharma firm is... Read more »
As president-elect, Donald Trump in January 2017 slammed drug companies for “getting away with murder” and said he supported Medicare negotiation. He vowed during last month’s State of the Union... Read more »
Dozens of medical organizations and patient advocacy groups are pushing back against so-called “right-to-try” legislation that passed the Senate in August and is now under consideration in the House. An open... Read more »
Bellicum Pharmaceuticals (NASDAQ: BLCM) of Houston divulged Wednesday that its lead T-cell therapy program BPX-501 has been put on hold by the FDA. The treatment, for certain people undergoing bone... Read more »
The United States has a new Health and Human Services chief who is expected to weigh in on the country’s drug-pricing debate. But how Alex Azar, a former pharma executive at... Read more »
Is the J.P. Morgan CRISPR rollercoaster ride over? As rain fell heavily in San Francisco Monday, the first day of the massive healthcare conference, biotech stocks did, too. At least three... Read more »
June 12, 2018
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.